The Sussex Drug Discovery Centre (SDDC) has embarked on a novel initiative by hosting Stratosvir Ltd, a pioneering UK early-stage cancer therapeutics company, as a private biotechnology tenant in its laboratory facilities.

Dr Antonio Postigo, co-founder and Chief Scientific Officer of Stratosvir said ‘We are thrilled to have opened laboratory facilities at Sussex. The Centre’s vast experience in drug development in collaboration with industry partners offers us an excellent environment in which to progress our systemically delivered anti-cancer viral therapeutics’.

Director of SDDC, Prof Erika Mancini added that ‘We are delighted to welcome Stratosvir to our Centre.  Our mission is to facilitate translation of academic research through drug development, and as part of our strategy for industrial collaboration we are keen to work with promising early-stage companies such as Stratosvir.’

Nick Bull, Business Partnerships Manager stated that ‘as the first private biotechnology tenant to be welcomed onto campus, I'm looking forward to Stratosvir tapping into our vibrant academic culture and engaging with our talented student community. I'm confident that their innovative research into viral immunotherapy cancer treatments will prosper and enhance the depth of research endeavors at Sussex’.